본문으로 건너뛰기
← 뒤로

WNT7B drives a program for pancreatic cancer subtype switching and progression.

iScience 2026 Vol.29(3) p. 115050

Sprangers J, Bugter JM, Xanthakis D, Boekhout M, Kok RNU, Geurts VE, Clevers H, Brosens LAA, Dijk F, Rodríguez Colman MJ, van der Vaart JY, Maurice MM

📝 환자 설명용 한 줄

Hyperactivation of WNT signaling is a hallmark of cancer, often driven by increased expression of WNT ligands.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Sprangers J, Bugter JM, et al. (2026). WNT7B drives a program for pancreatic cancer subtype switching and progression.. iScience, 29(3), 115050. https://doi.org/10.1016/j.isci.2026.115050
MLA Sprangers J, et al.. "WNT7B drives a program for pancreatic cancer subtype switching and progression.." iScience, vol. 29, no. 3, 2026, pp. 115050.
PMID 41797924

Abstract

Hyperactivation of WNT signaling is a hallmark of cancer, often driven by increased expression of WNT ligands. In pancreatic ductal adenocarcinoma (PDAC), elevated WNT7B and WNT10A correlate with aggressive, basal-like disease and poor patient survival, but the mechanisms underlying this association remain unclear. Using patient-derived organoids, we show that WNT7B promotes proliferation and maintains basal-like transcriptional states by preventing differentiation toward a more classical PDAC signature. Clonal WNT7B reporter organoids reveal that WNT-high cells are heterogeneously distributed and stably coexist with WNT-low/negative lineages. Hybrid co-cultures demonstrate that WNT7B-expressing cells support the survival and growth of neighboring WNT-negative cells via short-range, contact-dependent signaling. These findings highlight the functional importance of heterogeneous WNT7B/10A expression in driving PDAC aggressiveness and suggest that targeted WNT inhibition may shift tumors toward a more differentiated, less aggressive state, offering potential therapeutic benefit.